Fig. 3: MET suppresses the protective efficacy of chemotherapy-based liver cancer vaccination.
From: The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination
a Strategy for evaluating the potential effects of MET in chemotherapy-based liver cancer vaccination. b–e MET deficiency enhanced the protective efficacy of chemotherapy-based liver cancer vaccination. Wild-type (WT) and MET-deficient (MET-KO) H22 cells (b, c) and Hepa1-6 cells (d, e) were individually treated with cisplatin (CDDP), oxaliplatin (OXP), or a vehicle control (Ctrl), respectively, and then subcutaneously (s.c.) injected into the left flank of C57BL/6 mice. One week later, all the mice were rechallenged with homologous untreated WT cells in the right flank. The tumor incidence is reported as Kaplan–Meier curves. Significance was determined by the means calculated with a likelihood ratio test. *p-Value < 0.05, **p-value < 0.01, ***p-value < 0.001, and ns (nonsignificant), compared to the indicated groups; n = 10 per group.
